GlassScriptPhysician profile
Lorelei D Punsalan
NPI 1679990618
$10,325.59
in general payments reported to CMS, 2019-2025
51 companies · $2,549 in 2025
The $2,549 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,884 · 2022: $1,941 · 2023: $1,964 · 2024: $1,988 · 2025: $2,549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,437 · Education: $63.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,436.68 |
| Education | $63.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $980.54 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $835.88 | 2021-2025 | |
| Biogen, INC. | $623.25 | 2021-2025 | Vumerity, Tysabri, Leqembi |
| Ucb, INC. | $600.64 | 2021-2025 | Rystiggo, Briviact, Fintepla |
| Acadia Pharmaceuticals INC | $478.99 | 2021-2025 | Nuplazid, Daybue |
| Abbott Laboratories | $460.83 | 2022-2025 | Infinity, Freestyle Libre 3 |
| Amgen INC. | $385.04 | 2024-2025 | Krystexxa, Uplizna |
| Regeneron Healthcare Solutions, INC. | $350.03 | 2022-2025 | Dupixent |
| Eisai INC. | $320.43 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $310.48 | 2021 | |
| Nevro Corp. | $305.18 | 2023 | Senza |
| Neurelis, INC. | $298.54 | 2021-2024 | Valtoco |
| Pfizer INC. | $293.23 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $272.97 | 2021-2025 | Andexxa, Wainua |
| Abiomed | $270.27 | 2025 |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $246.90 | 2021-2025 | Xcopri |
| Argenx US, INC. | $229.46 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Alexion Pharmaceuticals, INC. | $227.13 | 2021-2025 | Ultomiris |
| Kyowa Kirin, INC. | $214.35 | 2021-2024 | Nourianz |
| Merz Pharmaceuticals, LLC | $202.56 | 2022-2025 | Xeomin, Inbrija |
| Livanova USA, INC. | $175.87 | 2021-2022 | |
| Emd Serono, INC. | $174.45 | 2021-2025 | |
| Amylyx Pharmaceuticals, INC. | $166.09 | 2023 | Relyvrio |
| Biohaven Pharmaceutical Holding Company LTD. | $165.06 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $157.27 | 2022-2023 | Austedo Xr |
| Zoll Respicardia, INC. | $148.17 | 2021 | |
| Biosense Webster, INC. | $147.08 | 2025 | Nuvision Ice Catheter |
| Corcept Therapeutics | $109.99 | 2023 | Korlym |
| Jazz Pharmaceuticals INC. | $97.05 | 2022-2023 | |
| Amarin Pharma, INC. | $96.19 | 2025 | Vascepa |
| Lilly USA, LLC | $94.00 | 2021-2025 | Kisunla, Reyvow, Emgality |
| Scynexis, INC. | $77.86 | 2022 | |
| Edwards Lifesciences Corporation | $77.82 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Gilead Sciences, INC. | $76.37 | 2024 | Epclusa |
| Otsuka America Pharmaceutical, INC. | $72.90 | 2022-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.76 | 2023 | Ofev |
| Sunovion Pharmaceuticals INC. | $52.44 | 2021-2022 | |
| Celgene Corporation | $49.56 | 2022-2025 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $47.23 | 2022-2024 | Dysport |
| Lundbeck LLC | $46.36 | 2025 | Rexulti, Vyepti |
| Sumitomo Pharma America, INC. | $44.65 | 2023 | Aptiom |
| Horizon Therapeutics Plc | $41.90 | 2021-2023 | Uplizna |
| Catalyst Pharmaceuticals, INC. | $41.61 | 2024 | |
| Banner Life Sciences, LLC | $38.68 | 2023 | |
| Neurocrine Biosciences, INC. | $35.93 | 2022 | |
| Alnylam Pharmaceuticals INC. | $27.22 | 2021 | |
| Ani Pharmaceuticals, INC. | $25.15 | 2025 | Purified Cortrophin Gel |
| Medtronic, INC. | $24.24 | 2023 | Intellis Adaptivestim |
| Takeda Pharmaceuticals U.S.A., INC. | $22.01 | 2022 | |
| Grifols USA, LLC | $16.63 | 2023 | Gamunex-C |
| Supernus Pharmaceuticals, INC. | $14.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorelei Punsalan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.